NKMAX CO., Ltd.

KOSDAQ:A182400 Stock Report

Market Cap: ₩172.7b

NKMAX Past Earnings Performance

Past criteria checks 2/6

NKMAX's earnings have been declining at an average annual rate of -8.7%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 7.6% per year.

Key information

-8.7%

Earnings growth rate

-5.2%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate7.6%
Return on equity-19.4%
Net Margin149.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Introducing NKMAX (KOSDAQ:182400), A Stock That Climbed 96% In The Last Year

Feb 10
Introducing NKMAX (KOSDAQ:182400), A Stock That Climbed 96% In The Last Year

Revenue & Expenses Breakdown

How NKMAX makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A182400 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2410,47515,64443,1928,062
31 Dec 2310,7695,26148,2779,441
30 Sep 2310,945-66,60943,7739,819
30 Jun 2310,997-38,99938,4909,950
31 Mar 2310,728-54,67735,89610,400
31 Dec 2211,263-53,50535,8649,895
30 Sep 2211,705-60,70537,8549,765
30 Jun 2212,159-50,88237,0079,990
31 Mar 2212,771-50,55836,04710,235
31 Dec 2113,020-50,33636,1419,355
30 Sep 2112,605-40,89535,1268,898
30 Jun 2111,959-49,14834,3118,682
31 Mar 2111,234-45,05033,9327,788
31 Dec 2010,372-41,43931,4908,189
30 Sep 209,416-45,71927,1189,538
30 Jun 209,169-40,78724,1878,738
31 Mar 208,722-16,10721,2777,522
31 Dec 198,749-11,42918,9216,505
30 Sep 197,825-5,34415,9804,932
30 Jun 197,085-4,27814,4004,300
31 Mar 196,824-22,05814,1744,479
31 Dec 186,269-20,45313,5774,655
30 Sep 185,913-20,31814,6425,120
30 Jun 185,677-18,88514,9175,203
31 Mar 185,155-17,47314,3955,118
31 Dec 174,830-16,63213,8535,093
30 Sep 177,253-9,96912,6683,656
30 Jun 177,091-5,86611,4313,545
31 Mar 176,855-4,9609,7683,688
31 Dec 166,876-4,8379,1203,913
30 Sep 164,140-7,2287,8383,835
30 Jun 163,578-8,3907,2423,769
31 Mar 163,228-5,5935,4043,108
31 Dec 152,513-5,3745,2232,724
30 Sep 152,001-5,9705,3262,597
30 Jun 151,777-5,8504,4422,471
31 Mar 151,732-6,1664,2252,484
31 Dec 141,678-5,8403,7602,313
31 Dec 131,503-3,1812,562732

Quality Earnings: A182400 has a high level of non-cash earnings.

Growing Profit Margin: A182400 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A182400 has become profitable over the past 5 years, growing earnings by -8.7% per year.

Accelerating Growth: A182400 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A182400 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).

Return on Equity

High ROE: A182400's Return on Equity (-19.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/22 19:24
End of Day Share Price 2024/03/25 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NKMAX CO., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jinhee KwakEugene Investment & Securities Co Ltd.
Wan KuNH Investment & Securities Co., Ltd.
Jiyong LeeShinhan Investment Corp.